The progression of renal fibrosis to end-stage renal disease (ESRD) is significantly influenced by transforming growth factor-beta (TGF-beta) signal pathway. This study aimed to develop nanoparticles (PMVs@PLGA complexes) with platelet membrane camouflage, which can transport interfering RNA to target and regulate the TGF-β1 pathway in damaged renal tissues. The aim is to reduce the severity of acute kidney injury and to reduce fibrosis in chronic kidney disease. Hence, we formulated PMVs@TGF-β1-siRNA NP complexes and employed them for both in vitro and in vivo therapy. From the experimental findings we know that the PMVs@siRNA NPs could effectively target the kidneys in unilateral ureteral obstruction (UUO) mice and ischemia/reperfusion injury (I/R) mice. In animal models of treatment, PMVs@siRNA NP complexes effectively decreased the expression of TGF-β1 and mitigated inflammation and fibrosis in the kidneys by blocking the TGF-β1/Smad3 pathway. Therefore, these PMVs@siRNA NP complexes can serve as a promising biological delivery system for treating kidney diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijpharm.2024.124261 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Significance of Biogenetic Markers in Giant Cell Tumor Differentiation and Prognosis: A Narrative Review.
Diagnostics (Basel)
December 2024
Orthopedic Surgery, Macquarie University Hospital, Sydney, NSW 2113, Australia.
: Giant cell tumor of bone (GCTB) is a locally aggressive tumor. It accounts for only 5% of all bony tumors. Early diagnosis, and follow-up for recurrence is often difficult due to a lack of biogenetic markers.
View Article and Find Full Text PDFEvaluation of the Effects of Autologous Leukocyte- and Platelet-Rich Fibrin Membranes for Treating Chronic Wounds: A Prospective Study.
Animals (Basel)
January 2025
Department of Veterinary Medicine and Animal Production, University of Naples "Federico II", 80137 Naples, Italy.
(1) Background: The aim of this prospective study was to evaluate the efficacy of topical application of leukocyte- and platelet-rich fibrin (L-PRF) membranes for treating chronic cutaneous wounds in dogs. (2) Methods: Chronic wounds unresponsive to conventional treatments were assessed on digital photographs and classified using the Bates-Jensen Wound Assessment Tool (BWAT). Each lesion was treated with L-PRF membranes.
View Article and Find Full Text PDFCorrection to: Adjunctive therapy for root coverage with concentrated growth factor versus platelet-rich fbrin membranes: a systematic review and Bayesian network meta-analysis.
Clin Oral Investig
January 2025
Department of Periodontics, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Increasing Bone Regeneration in Maxillary Sinus Augmentation Using Platelet-rich Fibrin: An Interventional Pre-Post Study.
J Contemp Dent Pract
September 2024
Department of Pediatrics Dentistry and Orthodontics, Faculty Odonto-Stomatology, Can Tho University of Medicine and Pharmacy, Can Tho City, Vietnam.
Aim: This study aimed to evaluate the impact of a combination of immediate implant placement with maxillary sinus augmentation (MSA) solely using platelet-rich fibrin (PRF) on guided bone regeneration.
Materials And Methods: An interventional before-after (pre-post) study design was used with 30 dental patients (≥18 years of age; 14 males and 16 females) with initial bone heights ranging between 4 and 6 mm. Following the general check-up and the creation of a study model, the planned implant location demonstrated an external right maxilla diameter of more than 5 mm, thereby validating the cone-beam computed tomography (CBCT) radiograph.
[Study on the safety profile of dual plasma molecular adsorption system application in patients with liver failure and refractory hyperbilirubinemia].
Zhonghua Gan Zang Bing Za Zhi
December 2024
Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu61004, China.
To retrospectively analyze the dual plasma molecular adsorption system (DPMAS) treatment technology and the laboratory data before and after treatment in patients with liver failure and refractory hyperbilirubinemia, so as to provide a clinical basis for the prediction and prevention of common related complications. A retrospective study was conducted on 161 cases with liver failure and 68 cases with refractory hyperbilirubinemia who underwent DPMAS treatment in our department from October 2022 to July 2024. The general clinical data characteristics, DPMAS treatment status, DPMAS-related complications, and changes in important laboratory indicators before and after the initial DPMAS treatment in both patient groups were analyzed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!